Brendon Binneman

Summary

Affiliation: Pfizer Global Research and Development
Country: USA

Publications

  1. doi request reprint A 6-week randomized, placebo-controlled trial of CP-316,311 (a selective CRH1 antagonist) in the treatment of major depression
    Brendon Binneman
    Pfizer Global Research and Development, M S 8260 2604, Groton, CT 06340, USA
    Am J Psychiatry 165:617-20. 2008
  2. ncbi request reprint Cerebral metabolic effects of intravenous glycine in healthy human subjects
    Alexander Neumeister
    Department of Psychiatry, Yale University School of Medicine, New Haven, CT 06516, USA
    J Clin Psychopharmacol 26:595-9. 2006

Detail Information

Publications2

  1. doi request reprint A 6-week randomized, placebo-controlled trial of CP-316,311 (a selective CRH1 antagonist) in the treatment of major depression
    Brendon Binneman
    Pfizer Global Research and Development, M S 8260 2604, Groton, CT 06340, USA
    Am J Psychiatry 165:617-20. 2008
    ..This study was designed to evaluate the safety and efficacy of CP-316,311, a selective nonpeptide antagonist of corticotropin-releasing hormone type 1 (CRH(1)) receptors, in the treatment of recurrent major depressive disorder...
  2. ncbi request reprint Cerebral metabolic effects of intravenous glycine in healthy human subjects
    Alexander Neumeister
    Department of Psychiatry, Yale University School of Medicine, New Haven, CT 06516, USA
    J Clin Psychopharmacol 26:595-9. 2006
    ....